News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

KaloBios Files for Bankruptcy Following Shkreli Arrest

January 4, 2016

Article

January 04, 2016.

Following the arrest on December 17 of former CEO Martin Shkreli, KaloBios Pharmaceuticals (South San Francisco, CA) filed for bankruptcy last week. According to Bloomberg Business, the company plans to use the bankruptcy to buy time to implement its restructuring plans. Shkreli, who took charge of KaloBios just a month ago, was arrested on fraud charges related to his position at his former company, Retrophin. KaloBios fired the controversial CEO shortly after his arrest. http://www.bloomberg.com/news/articles/2015-12-30/shkreli-s-former-biotech-company-kalobios-files-for-bankruptcy-iisup3fw

Related Content

AI in Pharma: Where, When, and How Executives are Considering it

Gaugarin Oliver

November 19th 2024

Article

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problems

Mike Hollan

November 15th 2024

Article

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Leap Forward: Practical Gains for Pharma AI Use

Bianca Anghelina;Helen Merianos;Ruth Beadle

November 14th 2024

Article

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.